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Alexander Emanuel Velázquez: CORONARY ARTERY DISEASE: AN ANALYSIS OF ITS 
BIOCHEMICAL, PHYSIOLOGICAL, AND SOCIOLOGICAL CAUSES AND EFFECTS 
 
 
Coronary Artery Disease (CAD) is a serious condition caused by a buildup of plaque in your 
coronary arteries, the blood vessels that bring oxygen-rich blood to your heart. It 
disproportionately affects millions of Americans and thousands of Mississippians. This study 
presents the results of an evaluation of causation factors of CAD, the physiological impact on the 
body, and the contributing determinants of CAD on Mississippi populations. Data on Mississippi 
populations were collected using the Center for Population Studies at the University of Mississippi. 
A multitude of individuals were evaluated when examining the causes and effects of CAD 
including men, women, children, and the elderly. The evaluation processes and procedures of all 
facets of CAD are given in great detail, so that this paper depicts the evolution of the evaluation, 
including changes in methodologies and treatment instruments in dealing with CAD. The findings 
of this research reflect the challenges faced by providers / public health officials in dealing with 
CAD in Mississippi. Findings for each of the aforementioned results are presented along with a 
discussion of what changes have been made or not made to aid the issue and why. While the 
findings of CAD’s effect on Mississippi populations is not generally quite positive, the 
improvement in the detrimental effects of CAD in recent years clearly allows the possibility of 
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Within this chapter I hope to explain the meaning of what occurs on a cellular level within 
the body during Coronary Artery Disease. The causes, effects, and what happens elsewhere in the 
body will be explained here. Coronary Artery Disease does not occur overnight. The severity of 
the disease as it unfolds will be discussed in this chapter. First, I need to defined the relevant 
vascular structure that is in play as the disease develops. Next, I will develop the story of the 
inflammatory processes and pathology of the disease, and then the immediate macroscopic 
manifestations of coronary artery disease in health. 
DEFINITION OF CORONARY ARTERY DISEASE 
A coronary artery is a blood vessel that feeds the heart, a muscle that must run aerobically 
in order to have the ATP to ensure its continued contraction. Coronary Artery Disease (CAD) is 
damage or disease in the heart's major blood vessels. The usual cause is the buildup of “plaque,” 
a colloquialism that is convenient to use and will be used throughout this document, but will be 
defined properly below. Plaque buildup causes coronary arteries to narrow, limiting blood flow to 
the heart. Coronary artery disease can range from no symptoms, to chest pain (angina), to shortness 
of breath, to fatigue and nausea, to a heart attack. A heart attack, also called a myocardial 
infarction, occurs when the flow of blood to the heart is blocked restricted to the point that the high 
demand for oxygen cannot be met by the restricted blood flow, and the heart muscle cannot 
continue to contract in locally or globally. Plaques are most often due to a buildup of fat, 
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cholesterol and other substances. Plaque can weaken the vascular wall and lead to additional 
problems as discussed below.1 
In order to begin the discussion of the formation of plaques, called atherogenesis, we must 
first review the structure of vascular tissue. Coronary arteries are much more than just pipes for 
blood flow to feed the heart muscle, they have multiple layers with different properties and 
purposes. Blood vessels are lined with Endothelial cells, a sheet of cells similar to epithelial cells, 
but generally more permeable to small solutes and water. There are various tissues connected to 
the heart that are involved in this buildup of plaque, and these tissues range from the tunica, intima, 




Figure 1: Definitions of key players 
(A) Artery Structure. From the center out: Tunica interna or “Intima” comprised of the 
endothelium, a subendothelium and a layer of connective tissue (elastic lamina), Tunica Media 
comprised of the smooth muscle layer and another layer of connective tissue (elastic lamina). 
Figure from https://en.wikipedia.org/wiki/Artery. 
(B) Illustration of coronary arteries and Plaque inside a coronary artery. 
Coronary arteries feed the heart muscle itself. Thus, blockage of a coronary artery means that 
the heart muscle is oxygen starved. Illustration of a plaque in a coronary artery.  
Figure taken from https://www.wnyurology.com/content.aspx?chunkiid=11986 (Copyright © Nucleus 




TISSUE BIOLOGY OF ATHEROGENESIS  
Coronary Artery Disease is not only a cholesterol storage disease, it is now known to be a 
complex interaction of risk factors including cells of the artery wall and the blood, and molecular 
messages that they exchange. While the accumulation of plaque within these arteries can couple 
with a variety of physiological effects (Chapter 3), for now, we will focus on the very local events 
in the coronary artery itself. There is a plaque, and the possibility for the formation of a blood clot 
that forms due to tissue remodeling and weakening, and the amplification of the problem because 
of these two coupled events. As described below, there is due to a complex interplay between clot 
formation and recruitment of immune cells and plaque formation. 
This story begins with a diet that is atherogenic.2 Specifically, this term refers to the 
tendency of a diet that will lead to the persistence of a particular form of Low Density Lipoproteins 
in the blood that are depleted of most of their Triglyceride cargo, slow to clear from the blood 
plasma, have abnormal association of immune cells with the arterial wall, and are particularly 
sensitive to oxidative stress.3 In studies of rabbits that are fed an atherogenic diet, the expression 
of vascular cell adhesion molecule-1 (VCAM-1) is up regulated in the arterial endothelial cells.4 
Subsequently, interactions between monocytes, a leukocyte present in the blood, adhere to VCAM-
1 and migrate into the intima, the innermost section of the artery or vein. This process begins 
within 12 days of the start of a high lipid diet in eukaryotic cells with association and migration of 




Figure 2. Participation of inflammation in all stages of atherosclerosis.5  
(A) When cardiac endothelium becomes inflamed, it expresses VCAM-1 that binds monocytes from the 
blood. Monocytes transform to fat filled macrophages causing stenosis of the cardiac artery. Macrophages 
differentiate into dendritic cells.6 
(B) T lymphocytes are recruited to the dendritic cells further add to the secretion of cytokines and growth 
factors that promote remodeling smooth muscle cells (SMCs) and the elastin and collagen network. of the 
migration and proliferation of SMCs. Medial SMCs express specialized enzymes that can degrade the 
elastin and collagen in response to inflammatory stimulation.7 
(C) Ultimately, inflammatory mediators can inhibit collagen synthesis and evoke the expression of 
collagenases by foam cells within the intimal lesion. Thus, when the plaque ruptures, as shown here, the 
tissue factor induced by the inflammatory signaling triggers the thrombus that causes most acute 
complications of atherosclerosis. 
 
Within 12 weeks of this process, foam cells within the intima are shown to form the “fatty 
streaks” that are precursors to plaque, and the very monocytes, now called macrophages, that are 
the cell that are the “foam” cell. Transmigration of the leukocytes typically is dependent on the 
expression of chemoattractant cytokines regulated by signals that are associated with traditional 
and new risk factors for CAD. Once they arrive at the arterial intima, the leukocytes present, which 
are mainly mononuclear phagocytes and T lymphocytes, communicate with smooth muscle cells 




The presence of large aggregates of lipid filled macrophages then became associated with 
focal defects in the endothelial lining that exposed collagen, and in some models, platelet adhesion 
was seen in such areas (Figure 2C). Due to the inflammatory ferment that occurs in early 
atherogenesis, SMCs move away from the tunica media, the middle layer of and within the intima. 
These cells then undergo proliferation and form a thick extracellular matrix. In conjunction with 
endothelial cells and monocytes, the SMCs secrete matrix metalloproteinases (MMPs) that 
respond to the various oxidative, inflammatory, and autoimmune signals received. MMPs are in 
balance with their endogenous tissue inhibitors, and they moderate various functions of vascular 
cells that include activation, proliferation, migration, and cell death. More importantly, they can 
moderate new vessel formation, geometric remodeling, healing, or destruction of extracellular 
matrices of arteries and the myocardium.8 
 A recent review by Bäck, et al (2019) provides cellular level insight into observations made 
two decades earlier. Libby, et al noted that the appearance of the fat streaks was associated with 
an increase in the adhesion of monocytes to the endothelial surface, suggesting that lipid filled 
macrophages have a dynamic relationship with the intima.5 Figure 3 below illustrates indeed there 
is an active dynamic between LDL and the cell surface which would be directly reflected in the 
nature and fate of the “foam” cell, i.e. lipid filled macrophages.9 Macrophages have a range of 
phenotypes that range from very pro-inflammatory to anti-inflammatory. As discussed above 
macrophages envelop LDL leading to transdifferentiation into a foam cell (center of Figure 3). 
SMCs also form foam cells (left side of Figure 3) like the macrophages do and there is evidence 
that both of these cells can migrate back out of the intima- anti-inflammatory macrophages 
carrying the inflammatory lipids out of the tissue. If the load of transdifferentiated SMC and 
macrophages is high, then they release pro-inflammatory chemicals into the now inflamed intima. 
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This leads to further decline, and apoptotic cells creating a necrotic core of lipid waste in the intima 
that is to become the “plaque” of concern here. The plaque itself is responsible for secreting pro-
inflammatory cytokines.9 
 
Figure 3. Macrophage life cycle and cholesterol round trip in atherosclerosis.9 
The central portion of the figure shows the penetration of monocytes and their transformation to 
macrophages in the intima layer. The more pro-inflammatory signals that are in the tissue, the more 
monocyte penetration and transformation. On the left, cholesterol from LDL accumulates and is taken up 
and transforms both macrophages and smooth muscle cells thereby creating “foam” cell versions of each. 




Proteoglycans in the extracellular matrix bind lipoproteins and prolong their occupation of 
the intima, thus making them more susceptible to oxidative stress and glycation. These products 
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of lipoprotein modification, including oxidized phospholipids and glycation end products, receive 
and spread the inflammatory response. As the lesion enlarges, calcification can then happen 
through processes similar to those in bone formation. Along with proliferation, cell death 
frequently occurs alongside within the atherosclerotic lesion that occur when accumulations of 
lipid, cells, and matrix components, including minerals, are associated with structural 
disorganization, repair, and thickening of the intima, as well as deformity of the arterial wall. The 
death of lipid-full macrophages leads to extracellular deposition of tissue factor (TF). The 
extracellular lipid that gathers within the intima can accumulate and create the lipid-rich “necrotic” 
core of the atherosclerotic plaque which will then go onto form the plaque that fills the arteries 
within our hearts.8  
 
FROM A MACROSCOPIC VIEW 
While death and other health complications of CAD are due to cardiac arrest, not all of 
these complications are cardiovascular in origin. The heart can be damaged as a result of 
respiratory failure or cerebral failure. Therefore, death can be defined as cerebral, respiratory, or 
cardiovascular issues.  
In a cerebral setting, cardiac arrest occurs in the setting of brain apoplexy which is an effect 
of a hypertensive hemorrhage. This hemorrhage can occur in the acute cerebral edema, where 
cardiorespiratory centers are located, and lead to a tragic loss of autonomous central respiratory 
functions. The heart will then begin to stop and cardiac arrest will commence. Sudden death can 
occur during epileptic seizures that are associated with respiratory chest muscle paralysis. Within 
patients diagnosed with epilepsy, there is a 20-fold increased risk of sudden death compared to 
those with the same risk factors who are not diagnosed with epilepsy.  
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In a respiratory setting, a simple airway obstruction can occur and lead to an acute failure 
of ventilation and alveolar gas exchange, which produces hypoxia and final heart failure. This is 
an example of the “chest pain” commonly associated with the onset of heart failure. Within the 
walls of the bronchitis, eosinophil release by inflammatory cells can jeopardize function due the 
thickening of the bronchial walls. In situations where patients undergo unconsciousness, this 
occurs during airway obstruction where ventilatory function is endangered, but circulation and 
brain function is preserved during the attack.  
Finally, in a cardiovascular setting is where plaque can have such an immediate effect on 
health. Plaque forming within the aorta or pulmonary artery can impede blood flow. Plaque 
residing within any one of the major cardiac structures, whose integrity is critical for regular heart 
function, is critical not only in blood flow but for maintenance of electric impulse propagation 
during regular pace-making functions. A dysfunction of any of these structures that is sudden can 
lead to the instantaneous death that is seen during severe heart attacks or strokes. Overall, over 
50% of coronary heart disease is attributed to cardiovascular mechanisms due to plaque 








In this section of the thesis, I will explore the topic of the footprint of general health, 
lifestyle and access to healthcare correlate with the occurrence of coronary artery disease in 
residents of the state of Mississippi. The information in this section is statistical in nature, but 
paints a clear picture of the challenges our state faces.  Every year an average of 1,700 people in 
Mississippi die from coronary heart disease. In 2016, CAD was the sixth highest cause of death in 
Mississippi, accounting for approximately 5.4% of all deaths. Unfortunately, the death rate due to 
coronary heart disease in 2016 was 1.4 times higher than that of the national rate, and it 
disproportionately affected African Americans and men. In 2000, Mississippi had the sixth highest 





Figure 4: American Heart 
Association Fact Sheet for the 
state of Mississippi: 2010 fact 
sheet. 
 
Notice that in 2010 the state of 
Mississippi was FIRST in the 









Trends in MS 
Assessing trends in stroke deaths by race and sex would provide important information for 
community and population health program managers, policy makers, advocacy organizations, and 
health professionals as they seek to spread stroke awareness, prevention, and treatment programs 
that address stroke disparities in Mississippi. There are few studies that have examined annual 
changes in stroke death rates in Mississippi. To address this gap, researchers with the American 
Heart Association calculated the annual percentage change (APC, trend segment) and the average 
annual percentage change (AAPC) in age-adjusted stroke death rates among Mississippi adults 
aged 35 or older from 2000 to 2016. In addition, they examined differences in the AAPC by age, 
sex, and race. Below are listed some of the risk factors within Mississippi residents. 
 
TABLE 1: Heart Disease and Stroke Risk Factors in Mississippi 
Individuals MS US 
Adults who are current smokers 26% 21.1% 
Adults who participate in more than 50 min of aerobic physical 
activity per week 
40% 51.5% 
Adults who are overweight or obese 68.9% 63.5% 
Adults who have been told they have had a heart attack 5.4% 4.4% 
Adults who have been told they have had a stroke 4% 2.9% 
Adults who have been told they have angina or CHD 4.6% 4.1% 
Population of adults (16-64) who have health care coverage 69.3% 78.9% 






To affect the burden of heart disease and stroke in Mississippi, programs implemented must 
reduce the incidence of preventable risk factors: Physical Inactivity, Poor Nutrition, and Tobacco 
Use. Currently, 84 percent of the adult population has one or more of these risk factors. 
Additionally, 2.8 percent have the “deadly quartet”: high blood pressure, high cholesterol, 
diabetes, and obesity. Lawmakers in Mississippi have created plans to address these risk factors in 
a two-fold approach: prevention of potential risk factors and management of existing risk factors. 
Risk factors addressed with the prevention approach include the lack of regular physical activity, 
improper nutrition, and tobacco use. Increasing physical activity and proper nutrition can prevent 
many of the other risk factors such as obesity, diabetes, high blood pressure, and high blood 
cholesterol. Reducing tobacco use will also contribute to reducing high blood pressure and high 
cholesterol. The second approach is to manage existing risk factors. While the hope is to prevent 
cardiovascular disease through lifestyle changes, programs and interventions must be developed 
to deal with the population that does acquire these risk factors. These risk factors include 
hypertension, obesity, abnormal cholesterol, and diabetes. The plan also discusses socio-cultural 
factors that influence cardiovascular health. For each risk factor the Plan created includes 10-year 
objectives to achieve the stated goals and addresses specific actions needed in the community 
environment, worksites, and healthcare settings. For each setting, the Plan develops strategies 
based on collaborations/partnerships, program services, public awareness, and policies. The Plan 
discusses implementation of the strategies and evaluation in later sections.  
Physical Inactivity 
Regular physical activity is associated with a healthier, longer life. Physically active people 
have a lower risk of heart disease, high blood pressure, diabetes, obesity, and some types of cancer 
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than less active people. Therefore, a need exists for effective population-based interventions to 
promote increased physical activity. Although intensive physical activity is recommended for 
cardiorespiratory fitness, even moderate levels of physical activity can have significant health 
benefits.11 Physical activity does not need to be strenuous to achieve health benefits; people who 
are inactive can improve their health and well-being by becoming even moderately active on a 
regular basis. Even greater health benefits can be achieved by increasing the amount (duration, 
frequency, or intensity) of physical activity.12. Physically inactive people are almost twice as likely 
to develop CHD as people who engage in regular physical activity. The CHD risk from physical 
inactivity is almost as high as that from cigarette smoking, high blood pressure, and high 
cholesterol; and physical inactivity is more prevalent than any of these other risk factors.11, 13 







Optimal nutrition can help lower the risk of developing chronic diseases and their risk 
factors. High fat, high sugar, and low nutrient foods are quick, plentiful, inexpensive, and widely 
available. However, healthy eating is often perceived as being time-consuming, expensive, 
complicated, and/or unappealing. The trend for increasing portion sizes in restaurants continues, 
particularly in fast food and convenience stores where high fat foods and high sugar beverages are 
common. Larger sizes are heavily promoted in advertising and at point of sale. In many cases, 
these large portions far exceed recommendations of the USDA and FDA. Research shows that 
Americans are eating too much food with little nutritional value. High fat, high sodium, high sugar 
foods are even served in schools on a regular basis. More than 84 percent of children and 
adolescents eat too much fat and 51 percent eat less than one serving of fruit per day. Appropriate 
nutrition is one of the easiest ways to reduce key risk factors for cardiovascular disease such as 
high blood pressure, high cholesterol, obesity, and diabetes. Population-based strategies must be 
implemented to address access to food with high nutritional value, to educate the public on the 
necessity of consuming such foods, and to provide incentives to choose healthier alternatives.13  
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Tobacco use, in particular smoking, still remains the primary cause of preventable disease 
and death in the United States and in Mississippi. Since the year 2000, more than one million 
young teenage people have been introduced to or become regular smokers, and upwards of 400,000 
adults die from tobacco-related diseases in the United States. Tobacco dependence is primarily 
viewed as a chronic disease with waves of remission and relapse.14 Tobacco use throughout the 
nation has resulted in more than $50 billion annually in direct medical costs. Tobacco smoking 
kills more people each year than the AIDS virus, alcohol consumption, prescription drug abuse, 
car crashes, murders, suicides, and fires all combined with each other. Approximately 80 percent 
of adult smokers started smoking before the age of 18, and every day, nearly 3,000 young people 
under this age become regular smokers. More than five million children living today will die 
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prematurely because of a decision they will make as adolescents – the decision to smoke cigarettes. 
In addition to tobacco use, environmental tobacco smoke (ETS) exposure remains the third leading 
cause of preventable death in the United States today. Most state and local laws for clean indoor 
air reduce but do not eliminate nonsmokers’ exposure to ETS.14 What was the enabler for these 
terrible statistics? Our past governor was a wealthy man because he was a lobbyist for the tobacco 
industry. With the settlement from the lawsuit against the tobacco industry every state got money 
for smoking cessation programs. Our state initiated these programs, but then gutted them and used 
the money for something else- like for the school system. 
Even with all these astonishing facts, there is evidence that tobacco use in this nation can 
be reduced through existing types of interventions, in line with health objectives detailed in 
Healthy People 2010.15 Treating tobacco dependence is particularly important economically, as 
treatment can prevent a variety of costly chronic diseases, including heart disease, cancer, and 
chronic lung disease. It has been estimated that smoking cessation is more cost-effective than other 
commonly provided clinical preventive services, including screening for cervical, breast, and 
colon cancer; treatment of mild to moderate high blood pressure; and treatment of high.14 Most 
smokers become addicted at a young age. In fact, 90 percent of those killed by tobacco started 
smoking before the age of 18. Therefore, preventing young people from using tobacco will help 
them to live longer, healthier lives.16 Even for nonsmokers, reduced smoking rates mean a better 
quality of life. Every year, Mississippi taxpayers foot the bill for an estimated $320 million tax 








As time has progressed, the success rate of this plan has become apparent. Within a 2017 
study performed by Jackson State University, the development of high blood pressure and obesity 
among African American Adolescents in Mississippi was explored. Childhood obesity has reached 
epidemic proportions and is linked to hypertension among African American youth in Mississippi. 
There is an apparent optimistic bias that influences behavior of youth causing them to 
underestimate their susceptibility to negative health outcomes. The study explored adolescent 
behaviors and prevalence of high blood pressure and obesity in a school district. The researchers 
examined the relationship between individual health risk practices and optimistic bias on health 
outcomes; 433 African American high school students were administered a survey and had their 
obesity and blood pressure measured by the school nurse. Canonical correlational analyses were 
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used to examine relationships between health risk practices and descriptive statistics for optimistic 
bias and health outcomes. Engaging in moderate exercise for at least 30 min in the last 7 days and 
lower blood pressure was the only statistically significant relationship. Two-thirds of the students 
did not perceive themselves to be at risk of developing cardiovascular disease with males at greater 
risk than females, despite the presence of clinical risk factors for hypertension and obesity. 
Reducing health optimistic bias is an effective way of motivating young people to adopt more 
positive behaviors using educational institutions to implement intervention programs that promote 
positive health behavior as a way to reduce health disparities. The cornerstone of cardiovascular 
health prevention and risk reduction in children and adolescents is characterized by a combination 
of lifestyle change and the adaptation of healthy behaviors that can become a major component of 
the education system curriculum. This is an important first step in the fight to reduce health 
disparities and health risks that plague many communities around America, and the State of 
Mississippi. As adult obesity and childhood obesity continue to escalate in Mississippi, education 
and awareness of the effects of the risk factors are important strategies that would motivate changes 
in behavior. Some researchers have stressed that inaccurate self-diagnosis can be a predictor of 
morbidity and mortality. So, it is important for communities to implement strategies that increase 
the potential for change in health status by implementing targeted person-environment public 
health interventions to ensure, not only accurate assessment of health status, but also the 
development of adequate prevention and intervention strategies. 
 Despite the overwhelming causative agents that are prevalent in Mississippi, how can we 
as a state improve in helping those already afflicted by heart disease? As previously mentioned, 
the population of Mississippians who currently own health insurance is 69%, currently 10% below 
the national average. The inability to pay for medical care could potentially lead to the disparities 
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across the board that are present in those afflicted by heart disease. As of July 2012, approximately 
one-third of the entire Mississippi population is classified as “underserved” by primary medical 
care. Primarily, there is a disparity across the state when it comes to the amount of primary care 
physicians with Mississippi ranking 48th in the nation. Despite gains to provide sufficient access 
to primary care, the lack of managed care options and lack of systematic integration amongst 
physicians, hospitals, and insurers.  
Another issue is Mississippi’s high rate of limited access to primary health care than people 
covered by private insurance or Medicare. However, access to health care does not equal access to 
primary care. An example of this is the inability to gain access to an appointment with a physician. 
The option of scheduling an appointment with physician extenders (nurse practitioners, physician 
assistants, registered nurses) or wait an extended period to see a primary care physician was rarely 
offered in a 2014 survey.17 The survey results showed that  consumers would gladly see a nurse 
practitioner or physician assistant, and research shows that nurse practitioners could be used to 
reduce the national shortage of primary care providers.18 Future research should explain the 
geographic differences in access to primary health care in relation to rural vs. urban areas in 
Mississippi. 
To put it simply, I would like to point out that the state's plan must address the structural 
realities that constrain health behaviors as discussed in the Kaiser website's page. In other words, 
it's great to integrate healthy eating and cooking education in public schools; but if you live in 
Marks, MS, you have no grocery store to buy healthy food.  Also, it's great to encourage people to 
take a walk, but if their neighborhood has no sidewalks or is dangerous, people are not going to 
want to take exercise outside. While access to health does determine health, Social determinants 
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of health also include factors like socioeconomic status, education, neighborhood and physical 
environment, employment, and social support networks.19 
In conclusion, Mississippians, who are some of the poorest and sickest Americans, have a 
lack of regular access to primary care that is concerning, especially since new research has been 
found that an expansion of Medicaid eligibility is associated with a significant decrease in 







GENETICS VS LIFESTYLE.  
 When observing what is the true causative agent of Coronary Artery Disease, there is no 
one true observable obstacle. The multitude of diseases that occur can be the effects of a lifetime 
of poor decisions, or they can be a result of a defection that was present at birth. While both play 
an important role in the formation of the disease, the majority of time is spent on lifestyle habits 
due to the fact that this is the most preventable cause of disease. However, I hope to show that 
both Genetics and Lifestyle can be causative agents in this disease. 
Genetic Linkage Analysis 
 In order to ascertain a particular specific gene with a particular cardiovascular disease, 
researchers primarily use linkage analysis and association studies. Linkage analysis has shown 
great levels of success in disease with simple, Mendelian patterns of inheritance that have a 
singular gene that displays tremendous phenotypic effect. The causal genetic mutation that can be 
ascertained using DNA sequencing that we are particularly interested is the Low-density 
lipoprotein receptor gene mutation (an exon deletion) that causes homozygous familial coronary 
artery disease. Researchers were able to find a correlation between the two, but even with the 
apparent genotype-to-phenotype linkage, there was not always a simple one-to-one correlation. 
Pleiotropy is the production by a single gene of two or more apparently unrelated effects, and can 
be observed by mutations in different sites on the same gene or distinct mutation at the same site 
leading to different outcomes. For example, one individual in a pedigree may exhibit cardiac 
arrhythmia, whereas another individual with the same disorder in either the same or different 
pedigree shows muscle weakness and deafness. Penetrance is the proportion of genotype carriers 
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who actually express a particular phenotype. For example, if a mutation in the gene responsible 
for a particular autosomal dominant disorder has 95% penetrance, then 95% of those with the 
mutation will develop the disease, while 5% will not. These two variabilities in expression can be 
the result of environmental factors or other “modifier genes” that are not identified by simple 
linkage analysis trials. Because of this, researchers have undertaken the role of association studies 
in order to find genetic causation for traits not obeying Mendelian Genetics. Some common genetic 
mutations that occur in patients with CAD are the mutations in low-density lipoprotein receptor 
by exon deletion causing homozygous familial hypercholesterolemia, missense mutations in 𝛃-
Myosin heavy chain (MYH7) that cause left-side lesions at birth, and nonsense mutations in 
transcription factor TBX that cause cardiac malformation.10  
 
Genome-wide Association Studies: 
 Genome-wide association studies (GWAS) have been the principal approach when 
identifying the genetic causations for traits with intricate inheritance patterns-traits that involve 
multiple genes that can potentially interact with environmental factors. As previously mentioned, 
clinical numbers such as lipid levels can occasionally have single Mendelian mutations that cause 
significant phenotypic effects. However, the majority of clinical values such as hypertension are 
influenced by multiple interacting genes with variant frequencies. While the trait itself will display 
Mendelian inheritance (as ascertained by a simple Punnett Square), the overall particular trait 
represents a nonlinear relationship of numerous different inputs, and therefore can be impacted by 
external factors. For the example of cholesterol levels, genetic variation in apoprotein synthesis 
and degradation, LDL internalization and processing, gastrointestinal lipid uptake, and receptor 




Figure 5: An illustration of a Manhattan plot depicting several strongly associated risk loci for 
mutations in the MYH7 gene on Chromosome 20. Each dot represents a single-nucleotide 
polymorphism which is when is a DNA sequence variation occurring when a single nucleotide in 
the genome (or other shared sequence) differs between members of a species or paired 
chromosomes in an individual, with the X-axis showing genomic location and Y-axis showing 




Current Available Testing  
In previous years before the current genetic understanding, there were a small number of 
well-defined instances where genetic testing was indicated, and most practitioners would approach 
these with confidence. In today’s world, genetic etiologies are as common as infections in 
differential diagnoses, and the complexity of analyzing results can be overwhelming. The first step 
is identifying a few key conditions as a clinician. The basic clue for a genetic etiology is the 
presence of family history of heart disease. An individual with a family with multiple related 
individuals being affected by heart disease, even if barely different in clinical appearances, 
supports an underlying genetic relationship. However, in a typical clinical setting genetic factors 
can be too complex to warrant genetic testing. This leads to the “grey area” that physicians must 
deal with when giving consideration to such presentations to determine if a diagnosable genetic 
condition exists. What makes this issue difficult is the idea of variable expressivity, or the degree 
to which a phenotype is expressed by individuals having a particular genotype. For example, in 
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2012 a Jackson, MS family was affected by congenital dilated cardiomyopathy. However, the 
individuals were diagnosed with a mix of severe heart failure, sudden cardiac death, and 
arrhythmia. By this same logic it can be assumed that some of the healthy individuals may have 
had the variant but never shown signs of the disease. Finally, the last major contributing factor as 
to why genetics can be difficult to research when studying family histories of CAD is that many 
of the mutations causing cardiovascular disease in affected individuals typically occur de novo.  
Lifestyle: Gene–environment interaction 
What effect can the physical environment have on the chemistry of our body? From the 
time we are born, we are given the genome that we have, but aside from natural mutations how 
can this genome change and develop into the genome that causes this disease? Nature vs nurture 
is the question here, and the answer is that both matter when determining Gene-environment 
interaction. Gene-environment interaction implies that in combination the effect of the genotype 
and the environmental factor under study deviates from the additive effects of the factors.  
Environmental risk factors 
There are various, distinct environmental variables that have the ability to influence lipid 
levels and increase the risk of CHD. These variables mainly include dietary fat, smoking, alcohol 
consumption, and lack of exercise. The problem researchers face in determining which of this is a 
causative factor is that quantifying these with any precision is incredibly difficult.22 Questionnaires 
are used to determine most of the environmental factors, but activities such as smoking or alcohol 
consumption might be under-reported and activities such as exercise perhaps be over-reported. 
Also, variables such as tar content are limiting factors in determining the impact of cigarette/e-
cigarette smoking. With things such as food consumption, daily food records of patients might be 
useful, but understanding the fat content and fatty acid composition of food is not as simple. What 
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would be most useful are biomarkers for environmental factors such as plasma measurements of 
by-products that can be numerically quantified. Examples of this include plasma cotinine, the 
major metabolite of nicotine, to measure cigarette consumption or levels of plasma linoleic acid 
as a measure of dietary compliance to dietary guidelines.  
The model for the relationship between genetics and environmental factors is shown in 
Figure 6. In the general population there is a variety of genetic risk profiles, with each person 
having a position along the risk spectrum varying from low to high genetic risk. Related individuals 
can position themselves differently on the environmental spectrum of risk by the differing life-
style choices they make. The important thing to remember is that the environmental risk factors 
are modifiable while the genetic risk factors are, unfortunately, not. Genomic environment 
interaction is important only when an individual with a high-risk genetic profile inhabits a high-







Figure 6. Model for gene–environment interaction.22  
This model proposes that each individual occupies a position on the genetic risk spectrum, 
depending upon how many risk-increasing gene variants have been inherited. Similarly, 
individuals are exposed to a range of environmental challenges depending on life-style choices. 
This theory proposes that risk of CHD only occurs when an individual at high genetic risk enters 
a high-risk environment, and genetic risks and environment risks alone will not trigger a CHD 
event. 
 
Alcohol consumption, alcohol dehydrogenase gene and CHD risk 
In order to statistically analyze gene-environment interaction for a quantitative trait that 
leads to CAD, such as alcohol dehydrogenase levels, is to use an analysis of covariance with the 
genotype and environmental factor entered as main effects and with an interaction term between 
the genotypic and environmental factors. An example of context dependency of a genetic variant 
on risk of CHD is the example of alcohol dehydrogenase. A common prescription to lower risk for 
heart disease in a glass of wine a day, and the way in which the beneficial effect of moderate 
alcohol consumption can be modified by variation in the gene for alcohol dehydrogenase. 
Moderate alcohol consumption has shown to be cardioprotective, thus the saying that “a glass of 
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wine a day keeps the cardiologist away.” The risk follows a J-shaped curve, such that individuals 
with a low alcohol intake are at greater risk than those who consume moderate amounts of alcohol, 
but as alcohol intake increases, the risk of CHD increases.  The alcohol dehydrogenase enzyme is 
an isoenzyme, which oxidizes ethanol. This enzyme is comprised of 3 subunits, ADH1A, B and 
C. Out of all three subunits, genetic variation in ADH1C is the most common and the best studied 
of the 3 genes. The ADH1C γ1 allele leads to fast oxidation of ethanol, but the γ2 allele results in 
a 2.5-fold slower rate of oxidation. Hines et al.23 showed that in an all-male nested case–control 
study drawn from the Physicians Health Study, a moderate consumption of alcohol of about 1 
drink/day was correlated with a decreased risk of myocardial infarction. This same study showed 
that the ADH1C genotype was also associated with a variation in CHD risk. The question the 
researchers then began to ask was ‘does alcohol intake modify the genotypic effects on CHD risk?’. 
In the male participants whose alcohol consumption was less than 1drink/week, the researchers 
were unable to find an apparent difference in the relative risk of myocardial infarction in γ2 carriers 
compared to γ1 homozygous men. The same could not be said for the group who consumed 1 or 
more drinks/day. In comparison to γ1γ1 low alcohol consumers, γ1γ1 moderate drinkers had a 
higher relative risk, while in γ2γ2 men the relative risk was lower. Therefore, variants in the alleles 
of a particular genotype can lead to a different relative risk when it comes to alcohol consumption. 
However, in part the risk reduction was defined by a larger increase in high density lipoprotein 
levels in γ2γ2 men, and the extent this genotype effect could be estimated by measures of habitual 







From a macroscopic viewpoint gene–environment interaction has great value because it 
shows the reduced risk in never- and ex-smokers and promotes the idea of quitting tobacco 
usage. Also, it shows the benefits of moderate alcohol consumption with a particular benefit in a 
genotype-specific manner. Therefore, the study of gene–environment interaction not only shows 
a meaningful way to improve our understanding of disease pathology at the molecular level, but 
also allows specific targeting of advice and therapies to high-risk subjects (those with a high-risk 







ANOMALIES OF CORONARY ARTERY DISEASE 
What makes CAD such a special disease? While we have examined the causes, detriments, 
and effects on the population that it might have, there still persists a need for such continuous CAD 
prevention, and research. The volatility of the causes, effects, and prevention methods are what 
make this disease so peculiar than other diseases. Overall, it is the effect that the disease can have 
on the entire body. Even King Solomon cited the heart as “the wellspring of life” and while others 
might argue that organs such as the brain or liver are more important, the heart is the “motor of the 
ship” that is the human body. In this section I hope to outline the potential anomalies that Coronary 
Artery Disease can present to the entirety of the body, despite being a disease that is correlated 
with the heart.   
Depression and Coronary Artery Disease 
Depression is considered to be a mental health disorder characterized by a disinterest in 
daily life and activities. It is typically correlated with an imbalance of neurotransmitters in the 
synapses of the brain. However, depression is a common illness displayed by patients with 
coronary heart disease, and these patients display risk factors for cardiac morbidity and mortality.24 
How could an illness correlated with the nervous system be impacted with a degeneration of the 
cardiovascular system?  
Depression is an illness associated with dysfunction in the autonomic nervous system; this 
in part might explain the increased risk factors in patients. Heart rate variability reflects how often 
the rhythm of the heart beats will change. Low heart rate variability typically occurs during 
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anaerobic exercise, psychological events such as anxiety attacks, or internal stressors such as 
excess cortisol levels. Low heart rate variability reflects excessive sympathetic and/or inadequate 
parasympathetic modulation of heart rate, and this is a strong predictor of mortality in patients 
with CHD. Higher heart rate variability typically means that the body has a strong ability to tolerate 
stress or is strongly recovering from prior accumulated stress. At rest, a high HRV is generally 
favorable and a low HRV is unfavorable. Various studies of both patients with stable CHD and 
patients that had recently had an acute coronary event have shown high heart rate variability to be 
decreased in patients with depression than with patients not diagnosed with depression. This can 
provide an overview of this conclusion and shows that HRV may account for a substantial part of 
the risk associated with depression in CHD. What could be the cause of this variability in heart 
rate?  
Depression has been linked with various behavioral and biological irregularities that could 
potentially explain the increase in risk of mortality in depressed patients with cardiac disease. 
These risks can, but are not limited to a reduced adherence to treatment advice given by physicians, 
an increase in prevalence of bad habits such as smoking, an increase in prevalence of diabetes, a 
formation of dysfunction in platelets and coagulation processes, inflammatory processes, and 
changes in autonomic nervous system function. Overall, all of these risk factors could potentially 
contribute to the increased risk for cardiac morbidity and mortality in patients diagnosed with 
depression. Autonomic nervous system dysfunction has shown on numerous occasions to be the 
most dangerous. Excessive sympathetic or reduced parasympathetic nervous system activity in 
patients diagnosed with CHD may lead to myocardial ischemia, ventricular tachycardia, 
ventricular fibrillation, and even sudden cardiac death. 
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Abnormal catecholamine levels, neurotransmitters that are released during stress, have been 
shown to be associated with CHD. Multiple studies that have been performed dating back to the 
1960s have shown that plasma and urinary catecholamine levels and resting heart rate levels to 
be elevated in medically well psychiatric patients with major depression in comparison to 
nondepressed controls. Studies of patients with CHD have also found elevated resting and 24-
hour HRs in depressed compared with nondepressed patients.  
 
Figure 7:  Potential mechanisms linking depression and coronary heart disease.25 
Additional evidence of ANS dysfunction in depressed CHD patients has shown an increased HR 
response to orthostatic challenge, increased QT interval variability that reflects abnormal 
ventricular repolarization, an abnormal HR response to ventricular arrhythmias (turbulence), and 
an increased incidence of ventricular tachycardia (HR over 100 bpm). All of these factors have 
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shown to have been related to ANS dysfunction, and all are great predictors of mortality in cardiac 
patients. 
Depression is a common psychiatric disorder in patients with coronary heart disease 
(CHD). Annually, 7% of Americans are diagnosed with major depression and the overall lifetime 
prevalence of major depression in the United States is approximately 16%. Of all the patients 
diagnosed with CHD, approximately 20% have major depression at any point in time. Also, about 
20% suffer from minor depression as well. When a patient suffers any acute coronary event, there 
is a 12 month period following it where up to 30% of patients may develop major depression. 
However, the amount of minor depression during this 12-month period has not been reported 
consistently, but is also estimated to be about 30%. Therefore, up to 60% of patients with an acute 
coronary event experience symptom of depression within the 12 months following the event. Why 
is this the case? 
Ultimately, this research does not prove the true relationship between depression, CAD, and 
mortality. However, these results do show that they are consistent with the idea that HRV and a 
combination of measures of HR response to stimuli may account for a significant percentage of 
depression’s relationship with mortality following a myocardial infarction.  
Diabetes and Coronary Artery Disease 
Diabetes mellitus is a disorder in which the body does not produce enough or respond normally 
to insulin, causing blood sugar (glucose) levels to be abnormally high. Interestingly, diabetes has 
been shown to have a prevalent link with coronary artery disease.26 Diabetes is treatable, but 
even when glucose levels are regulated and under severe control it greatly increases the risk of 
heart disease and stroke. The frequency of diabetes mellitus has reached enormous levels 
worldwide, and its frequency is only rising. A patient discovering they are diagnosed with DM 
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can lead to many things. The effects of a diagnosis of DM are as dangerous as a diagnosis of 
coronary artery disease. Also, DM (especially type 2 DM), is associated with risk factors for 
cardiovascular disease (CVD). There is a prevalence of 75% to 85% of hypertension, 70% to 
80% for elevated LDL, and 60% to 70% for obesity amongst adults with DM. While the patients 
undergo a glucose deficiency, CAD is the main cause of death in both type 1 and type 2 DM. 
DM is correlated with approximately a 2 to 4-fold increased mortality risk from heart disease. 
Also, in patients diagnosed with DM that are exposed to myocardial infarction, there is an 
increased mortality and patients typically express an overall worse long-term prognosis with 
CAD.  
Coronary artery disease is the greatest determinant of the long-term prognosis among 
patients with diabetes mellitus. Statins, a class of lipid-lowering medications that reduce illness 
and mortality in those who are at high risk of cardiovascular disease, are effective in reducing 
major coronary events, stroke, and the need for coronary revascularization. However, strict 
control of a patient’s glycemic index, or a measure of how much a specific food raises a patient’s 
blood glucose levels, for an average of 3.5 to 5 years has shown to not reduce cardiovascular 
events. This begs the question, how can a disease that deals with glucose and insulin have such 
drastic effects on the heart? Besides lifestyle habits that are common between CAD patients and 
DM patients, the main physiological culprit that researchers can deduce is the bridge between 
these two illnesses is hypoglycemia, the state of the body when blood glucose levels are lower 
than normal.  
Hypoglycemia and Mortality 
Hypoglycemia is a substantial, independent cause of excess morbidity and mortality. There are 
various mechanisms by which hypoglycemia might impact and or lead to cardiovascular events. 
These events that potentially lead to death from cardiovascular disease include sympathoadrenal 
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activation which is the release of chemical messengers to release a “fight or flight” response, 
abnormal cardiac repolarization which is an abnormal ion level during relaxation of the myocardial 
muscle, increased thrombogenesis which is blood clot formation, inflammation, and 
vasoconstriction leading to less blood flow in the arteries during recognized or unrecognized 
episodes of hypoglycemia.  
While the relationship between hospitalized patients with acute myocardial infarction and 
hypoglycemia is complex, there is a J-shaped curve relationship between glucose values and 
specific outcomes, such as increased mortality. Within this relationship, hypoglycemia has 
repeatedly shown to decrease myocardial blood flow reserve and increase experimental infarct 
size. Therefore, this correlation provides sufficient evidence for caretakers to attempt to mitigate 
the risk of hypoglycemia in patients with diabetes and CAD.  
How do physicians treat hypoglycemia? In order to remove the potential risk of the drastic 
cardiovascular events, physicians typically recommend to diabetic patients to keep blood glucose 
higher than average compared to non-diabetic patients. This is done through constant measurement 
of insulin levels, constant supplements of fast-acting carbohydrates such as fruits, or in drastic 





Figure 8: Management of Hypoglycemia in patients with acute coronary syndromes.26 
Iatrogenic hypoglycemia, or hypoglycemia that occurs due to overuse of blood glucose lowering 
medication, is the limiting factor in the glycemic management of DM. This condition typically 
occurs due to the interplay of mild-to-moderate absolute or relative therapeutic hyperinsulinemia 
and compromised physiological and behavioral defenses against falling plasma glucose 
concentrations. Because of this, physicians must take great precautions when prescribing insulin 
to diabetic patients as shown by the figure above.  
How thin people get heart disease 
As with any disease, there are certain cases that are unexplainable such as life-long smokers that 
never develop lung cancer. Unfortunately, heart disease is not a stranger to these anomalies, and 
the Behavioral Risk Factor Surveillance System database indicated in 2013 that the underweight 
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population had a 19.7% greater risk of CAD than did the normal-weight. While genetics was 
shown to play a role in determining risk factors for CAD, the majority of the concerns had to do 
with lifestyle, so how do “healthy” people have such a substantial increased risk compared to 
normal people? A genetic analysis performed on more than 75,000 people in the United Kingdom 
showed that lean people (i.e. normal weight individuals) that had a specific genetic variant had a 
higher chance of developing type 2 diabetes and heart disease even those individuals had a lower 
body fat. The answer has to deal with the type of fat that people are storing.27 
Most body mass indices detail how much body fat an individual might have, but it only accounts 
for the adipose tissue that is deposited under the skin. Researchers have discovered that not just 
the amount of fat individuals have, but the type of fat that is present in individuals is the key in 
determining the risk that thin people have. Repeated instances have shown evidence that the fat 
that is deposited under the skin does not contribute as much as previously believed to the 
development of heart disease and diabetes. However, fat that is accumulated in organs, within 
muscle, and fat that is buried within organs like the liver, for example, can have a greater risk of 
developing these metabolic diseases. This shows that thin people, who might not have much visible 
adipose fat, may be storing this “visceral fat” inside their body and organs. 
What bodily process regulates where fat gets stored in individuals? Sadly, the process of 
storing fat is largely genetic and gender based. Most women mainly tend to store subcutaneous fat 
under the skin, but men are more predisposed to having fat deposited deeper within the tissues and 
organs. As for the genetic reasons, researchers have identified one genetic variant out of more than 
2.5 million candidate sites on the genome linked to body fat. This genetic variant has been shown 
to predispose people to depositing visceral fat as opposed to the more benign subcutaneous fat. 
This visceral fat has been shown to impair muscle and organ function within the body. The power 
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of this genetic abnormality on metabolic factors such as cholesterol and triglyceride levels and 
insulin resistance were very noticeable. Thinner people with low body fat, but who were carriers 
of this version of the gene, constantly had elevated levels of blood cholesterol. These same 
individuals were more likely to display resistance to processing insulin, one of the primary signs 
of diabetes. However, most all of these individuals repeatedly displayed normal body mass index 
or BMI readings.  
Discussion 
Overall, this section outlines the reasoning behind as to why Coronary Artery Disease is 
not as easily diagnosable or treatable than other diseases. There are numerous anomalies that cause 
it, numerous dangerous outcomes that can occur due to it, and other metabolic factors to take note 
of after a patient is diagnosed with it. It is with great hope that one day there will be a way to 












 Coronary Artery Disease is a volatile disease that has many causes and outcomes that can 
occur throughout the body. Throughout the entirety of the literature, it is often commonly accepted 
that while lifestyle is the major factor causing the disease, it is not uncommon for genetics to have 
a severe impact as well. After studying the various impacts this disease can have on the body, 
individuals, and the other important outcomes this disease can lead to, I have found that there is 
significant cause for more extensive research, prevention plans, and patient care especially in 
Mississippi. This correlation between eating habits, poor lifestyle, and inability to provide quality 
access to care has been shown to be prevalent all throughout the South with Mississippi being a 
prime example. Perhaps there is a commonality between these states and their authorities that can 
explain in detail why this disease has become so prevalent to this day. Additionally, I propose that 
the historical events that have contributed to the growth and development of Mississippians 
resulted in a population that is more susceptible to develop coronary artery disease than any other 
population during this time. The results of this paper highlight the importance of statistical analysis 
of diseases in order to understand physiological differences in populations that live during this 
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